文献速递泌尿系结石

输尿管镜术后镇痛:酮咯酸与阿片类药物的双盲随机对照试验

SKOPE-Study of Ketorolac vs Opioid for Pain after Endoscopy: A Double-Blinded Randomized Control Trial in Patients Undergoing Ureteroscopy.
PubMed 文献 · J Urol · 2021-04-05

这项双盲随机对照非劣效性试验纳入81例输尿管镜碎石患者,比较按需口服羟考酮5mg与酮咯酸10mg的术后镇痛效果。两组疼痛评分、药物使用及副作用无差异,酮咯酸组卧床天数显著更少,支持非甾体抗炎药非劣效且可减少阿片类药物常规使用。

要点

  • 输尿管镜术后按需酮咯酸10mg镇痛效果不劣于羟考酮5mg。
  • 酮咯酸组卧床天数更少(1.3±1.3 vs 2.3±2.6,p=0.02)。
  • 两组药物使用、副作用及非计划就诊无差异。

核心结论

  • 非甾体抗炎药在输尿管镜术后镇痛中非劣效于阿片类药物,且恢复更早,不支持常规使用阿片类药物。

研究设计与样本

  • 双盲随机对照非劣效性试验,纳入81例输尿管镜治疗尿路结石患者,随机分为羟考酮组43例和酮咯酸组38例。

主要发现

  • 两组术后疼痛评分、研究药物或补救药物使用量及副作用均无差异。
  • 无论治疗分组,第1-5天最高疼痛评分较高(p<0.05)及问卷评分较高(28.1 vs 21.7,p=0.045)与镇痛药使用相关。
  • 酮咯酸组卧床天数显著少于羟考酮组(均值±SD 1.3±1.3 vs 2.3±2.6,p=0.02)。
  • 两组非计划术后医生接触无差异。

临床怎么用

  • 输尿管镜术后可优先选用酮咯酸10mg按需镇痛,减少阿片类药物处方。
  • 需告知患者酮咯酸组可能恢复更快,卧床时间更短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pain is the leading cause of unplanned emergency department visits and readmissions after ureteroscopy, making postoperative analgesic stewardship a priority given the current opioid epidemic. We conducted a double-blinded, randomized controlled trial, with noninferiority design, comparing nonsteroidal anti-inflammatory drugs to opiates for postoperative pain control in patients undergoing ureteroscopy for urolithiasis. MATERIALS AND METHODS: Patients were randomized and blinded to either oxycodone (5 mg) or ketorolac (10 mg), taken as needed, with 3 nonblinded oxycodone rescue pills for breakthrough pain. Primary study outcome was visual analogue scale pain score on postoperative days 1-5. Secondary outcomes included medication utilization, side effects, and Ureteral Stent Symptom Questionnaire scores. RESULTS: A total of 81 patients were included (43 oxycodone, 38 ketorolac). The 2 groups had comparable patient, stone, and perioperative characteristics. No differences were found in postoperative pain scores, study medication or rescue pill usage, or side effects. Higher maximum pain scores on days 1-5 (p <0.05) and higher questionnaire score (28.1 vs 21.7, p=0.045) correlated with analgesic usage, irrespective of treatment group. Patients receiving ketorolac reported significantly fewer days confined to bed (mean±SD 1.3±1.3 vs 2.3±2.6, p=0.02). There was no difference in unscheduled postoperative physician encounters. CONCLUSIONS: This is the first double-blinded randomized controlled trial comparing nonsteroidal anti-inflammatory drugs and opiates post-ureteroscopy, and demonstrates noninferiority of nonsteroidal anti-inflammatory drugs in pain control with similar efficacy, safety profile, physician contact and notably, earlier convalescence compared to the opioid group. This provides strong evidence against routine opioid use post-ureteroscopy, justifying continued investigation into reducing postoperative opiate prescriptions.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fedrigon D, Faris A, Kachroo N, et al. SKOPE-Study of Ketorolac vs Opioid for Pain after Endoscopy: A Double-Blinded Randomized Control Trial in Patients Undergoing Ureteroscopy. J Urol. 2021. PMID: 33819072. doi:10.1097/JU.0000000000001772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。